Compare SharkNinja Inc. Ordinary Shares (SN) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SharkNinja Inc. Ordinary Shares vs Travere Therapeutics Inc. Common Stock — how do they compare? SharkNinja Inc. Ordinary Shares trades at $186 (market cap $26.60B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: SharkNinja Inc. Ordinary Shares is far larger — about 5.5× Travere Therapeutics Inc. Common Stock's market cap, and SharkNinja Inc. Ordinary Shares is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SharkNinja Inc. Ordinary Shares for 3 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SN | TVTX | |
|---|---|---|
Market Cap | $26.60B | $4.88B |
Volume | 1,030,578 | 1,668,577 |
Sector | Consumer Cyclical | Health |
52-Week High | $192.86 | $67.52 |
52-Week Low | $84.57 | $26.79 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $26.73B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SharkNinja (SN) trades at $188.80, down 0.62% with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals with consistent earnings beats, 10.06% net margin, and robust cash flow growth. Recent product launches including new vacuum and kitchen systems highlight ongoing innovation. Analyst sentiment remains overwhelmingly positive with 91% buy ratings and a $202.18 consensus target.
SN presents a compelling growth story with strong profitability and product momentum, though elevated P/E of 38.5 suggests premium valuation. Key risks include consumer spending sensitivity and competitive pressures in home appliances. The stock's proximity to resistance at $192 requires monitoring for breakout confirmation.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About SharkNinja Inc. Ordinary Shares
SharkNinja designs and sells small household appliances under the Shark and Ninja brands. Its products include cleaning appliances, kitchen and beverage appliances, food preparation products, and beauty and home-environment devices.
Read more on SN →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
